Researchers at Monash University and the University of Melbourne reported de novo, AI‑designed anti‑CRISPR proteins (AIcrs) that inhibit Cas13a, validating hits in bacterial and human cells and compressing discovery to eight weeks. The work, published in Nature Chemical Biology, used RFdiffusion and ProteinMPNN to generate and prioritize candidates, then confirmed functional inhibition across assays. A separate press summary from Melbourne scientists describes similar AI workflows to control CRISPR activity, underscoring how generative protein design can produce off‑switches where natural inhibitors are scarce. For gene‑editing therapeutics, engineered anti‑CRISPRs act as molecular safety valves to limit nuclease persistence and reduce off‑target damage; this study demonstrates an accelerated route to build those safety tools. Clarification: Cas13 is an RNA‑targeting CRISPR effector used in diagnostic and therapeutic applications; anti‑CRISPRs are proteins that block CRISPR nuclease activity.